This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $193.74, marking a -1.79% move from the previous day.
Will Teladoc (TDOC) Survive Competition From Amazon's Entry?
by Zacks Equity Research
Teladoc's (TDOC) wide business scale, comprehensive product portfolio, wide clientele base, international operations poise it well to face competition from Amazon's foray into the virtual healthcare space.
Humana (HUM) Puts Senior-Focused Centers Under CenterWell Brand
by Zacks Equity Research
Humana (HUM) unveils the CenterWell brand, which will bring together the company's senior-focused primary care centers in a bid to offer personalized health care plans for senior patients.
Teladoc (TDOC) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $201.24, marking a +1.66% move from the previous day.
Humana (HUM) Unit Expands to Meet Senior-Focused Health Needs
by Zacks Equity Research
Humana's (HUM) subsidiary Conviva acquires a primary care physician network in South Florida for boosting healthcare services offered to seniors across the region.
Bulls & Bears Battle It Out In Big Tech
by Daniel Laboe
Yields are on the rise and valuation-propelled tech is getting deflated.
Bull of the Day: Align Technology, Inc. (ALGN)
by Benjamin Rains
Align Technology, Inc. (ALGN) is a new-age dental company, best known for its Invisalign system. The tech-focused firm posted back-to-back strong quarters to end 2020 on a high note and its outlook is impressive...
Stock Market News for Feb 26, 2021
by Zacks Equity Research
U.S. stock markets closed sharply lower on Thursday as rising bond yields raised concerns among market participants on risky assets like equities
Teladoc (TDOC) Q4 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Teladoc's (TDOC) Q4 earnings result reflects revenue gains, more than offset by flared-up expenses.
Case Shiller Home Prices Rose Better-Than-Expected In December
by Zacks Equity Research
Case Shiller Home Prices Rose Better-Than-Expected In December
Nasdaq Still Down as Rotation Continues, Home Depot Beats
by Mark Vickery
As we rotate back toward a more "normal" economy -- less dependent on "stay at home" activities -- we were bound to see some profit-taking with some of these biggest names of the pandemic.
5 Stocks That Make Ark Innovation ETF (ARKK) Red Hot
by Sweta Killa
ARKK is centered around the idea of disruptive innovation, which is defined as the introduction of a technologically-enabled new product or service that potentially changes the way the world works.
Teladoc (TDOC) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Teladoc (TDOC) closed at $287.86, marking a -1.15% move from the previous day.
Earnings Preview: Teladoc (TDOC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Teladoc (TDOC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $290.43 in the latest trading session, marking a +0.67% move from the prior day.
What's in the Offing for Centene (CNC) This Earnings Season?
by Zacks Equity Research
Centene's (CNC) Q4 results are likely to reflect escalating costs and other COVID-related factors.
Teladoc (TDOC) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teladoc (TDOC) closed at $263.83 in the latest trading session, marking a +0.38% move from the prior day.
What's in the Cards for HCA Healthcare (HCA) Q4 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) fourth-quarter earnings are likely to have witnessed better patient volumes and improved revenues.
Is Teladoc Health (TDOC) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (TDOC) Outperforming Other Medical Stocks This Year?
Higher Testing to Aid Quest Diagnostics' (DGX) Q4 Earnings
by Zacks Equity Research
Within non-COVID base business, Quest Diagnostics (DGX) is expected to have secured higher returns in Q4 from the acquisitions of MACL, Memorial Hermann Outreach and Blueprint Genetics.
Anthem (ANTM) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Anthem's (ANTM) fourth-quarter results benefit from higher revenues stemming from robust Medicaid and Medicare businesses, partly offset by higher costs.
Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings
by Zacks Equity Research
Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.
Thermo Fisher (TMO) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher's (TMO) Life-Science Solutions and Specialty Diagnostics segments are expected to have contributed, banking on COVID-19-led growing healthcare needs.
Anthem (ANTM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Anthem (ANTM) is likely to have witnessed increased revenues and a rise in membership during Q4, offset by an escalating expense level.
Here's Why You Should Add Teladoc (TDOC) to Your Portfolio
by Zacks Equity Research
Teladoc (TDOC) has been benefiting from strong revenues, higher telehealth visits and robust cash balance.